We synthesized carbon nanowalls (CNWs) using radical injection plasma-enhanced chemical vapor deposition. The initial growth process of CNWs was investigated with and without O2 gas addition to a C2F6 capacitively coupled plasma with H radical injection. In the case of the CNW synthesis without the addition of O2 gas, scanning electron microscopy (SEM), transmission electron microscopy, x-ray photoelectron spectroscopy (XPS), and Raman spectroscopy revealed that a 10-nm-thick interface layer composed of nanoislands was formed on a Si substrate approximately 1 min prior to CNW formation. In contrast, with O2 gas addition, SEM and XPS revealed that an interface layer was not formed and that CNWs were grown directly from nanoislands. Moreover, Raman spectroscopy suggested that the interface layer was composed of amorphous carbon and that O2 gas addition during CNW growth is effective for achieving a high graphitization of CNWs. Therefore, O2 gas addition has the effect of reducing the amorphicity and disorder of CNWs and controlling CNW nucleation.
Two-dimensional carbon nanostructures, carbon nanowalls (CNWs), were fabricated on a Si substrate using radical injection plasma-enhanced chemical vapor deposition, employing fluorocarbon (C2F6) and hydrogen (H2) mixtures. The influence of the surface conditions of the chamber wall on CNW growth was investigated in order to determine the optimum conditions for CNW growth with high stability and reproducibility. In order to monitor the surface conditions of the chamber wall, optical emission spectroscopy in the plasma was measured, and the correlation between CNW growth and the surface conditions in the chamber wall was investigated. The growth rate and morphology of grown CNWs were determined to be influenced by the surface conditions of the chamber wall. Furthermore, O2 plasma chamber cleaning followed by predeposition for passivation was found to be effective for maintaining steady conditions to attain CNWs with high reproducibility.
Hypothalamic hormones, including dopamine, regulate critical functions of pituitary cells via the cAMP-protein kinase A (PKA) pathway. The PKA-downstream transcription factor cAMP response element (CRE)-binding protein (CREB) is an integrating molecule that is also activated by many other protein kinase pathways. We investigated the involvement of CREB in the regulation of cell proliferation and the PRL promoter of rat lactotrophs in primary cell culture. Recombinant adenoviruses were used for efficient gene delivery into pituitary cells. Bromocriptine, a dopaminergic agonist known to decrease intracellular cAMP concentrations, caused inhibition of PRL promoter activity and lactotroph proliferation, which was accompanied by decreases in CRE-mediated transcription and CREB phosphorylation in lactotrophs. Expression of a dominant-negative form of CREB (MCREB), which was effective in suppressing CRE-mediated transcription induced by the adenylate cyclase activator forskolin, inhibited basal and forskolin-induced PRL promoter activity and PRL mRNA expression. MCREB expression lowered basal proliferative levels and blocked forskolin-induced proliferation of lactotrophs. Insulin-like growth factor I (IGF-I), a potent mitogen in lactotrophs, did not affect intracellular cAMP concentrations but transiently increased lactotroph CREB phosphorylation. MCREB expression also inhibited IGF-I-induced lactotroph proliferation. These results suggest that CREB is involved in the regulation of cell proliferation and the PRL promoter in normal lactotrophs and that dopamine inhibition of these lactotroph functions is at least in part due to inhibition of the cAMP-PKA-CREB pathway.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.